REVB Company Profile and Key Details

Revelation Biosciences, Inc. (NASDAQ:REVB) closed at $1.00 USD, losing -$0.01 (-1.05%) from the previous close of $1.01. The stock is currently mid-range between its 52-week high and low $0.88 and $8.40. With a market capitalization of about $3.91 million, Revelation Biosciences, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~-0.17). Key stats such as the average daily volume over the past year has been around 41.84 thousand shares, volume is running light vs its 52-week average. Headquartered in San Diego, CA, Revelation Biosciences, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO James Rolke, the company employs approximately 8 people and listed since November 17, 2020. Revelation Biosciences, Inc. is a biopharmaceutical firm currently in its clinical development phase, dedicated to the advancement and commercialization of treatments and diagnostic tools targeting the immune system.

REVB has shown mixed momentum, gaining 3.8% over the past week and -27.58% over the past quarter, though year-to-date performance is up 16.8%. Short-term trend indicators are bullishly aligned (SMA20 -13.61%, SMA50 -49.67%, SMA200 -83.43%). The stock’s 14-day RSI is 25.08 (weak momentum), while the ATR of 0.23 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -97.13% below its high and over 3.1% above its low. Average 10-day trading volume of 13.42 thousand shares is below the 3-month average of 39.67 thousand, indicating normal recent market interest.

Revelation Biosciences, Inc. has 3.91 million shares outstanding. The public float is 3.44 million shares, elevated short interest at 0.54% of float. This equals 20.20 thousand shares. The short ratio is 0.4 days. Institutional investors hold 13.43% of the float. Insiders own 4.79%.

Revelation Biosciences, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $1.60. This means the shares are trading below this model’s fair value.

Revelation Biosciences, Inc. generated EPS of -$120.21 over the past year. Five-year average earnings growth is -67.15%. Wall Street analysts project EPS growth of 77.71% annually over the next five years. The latest quarter delivered EPS of -$0.87. The next quarter is forecast at -$3.66. Next year's EPS is expected at -$50.98. Revelation Biosciences, Inc. earnings surprise history is a mixed track record. The quarter that ended August 07, 2026, missed forecasts by 4.82%. The prior quarter beat by 135.65%. Over the last six quarters, Apple has recorded several small beats. These include -69.33% in May 08, 2025.

Revelation Biosciences, Inc. trades at a P/E ratio of -0.14, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 0.38 suggesting the stock is closer to book value. The P/FCF stands at -0.42, also above market averages.

Revelation Biosciences, Inc. (NASDAQ:REVB) shares are up 16.8% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Revelation Biosciences, Inc. trading at a premium to the broader market with a P/E of -0.14. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $15.00, suggesting 1400.9% upside. Our AI forecast model points to short-term weakness (-3.94% over two weeks), a medium-term fall (-48.97% over three months), and a longer-term loss (-100.0% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Revelation Biosciences, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -3.94%, with price expected at $0.96 by September 24, 2026, within a range of $0.90 to $1.02 3-Month Outlook: Projected fall of -48.97%, reaching $0.51 by December 08, 2026, with a range of $0.33 to $0.69. 1-Year Outlook: Projected loss of -100.0%, with price at $0.00 by September 10, 2027, within a range of $0.00 to $8.31.